Page 1

context therapeutics Context Therapeutics Reports Second Quarter 2026 Operating and Pipeline Progress August 5 , 2026 Prioritization of CTIM - 76 and CT - 202 clinical programs , with initial clinical readouts expected beginning in Q2 2027 Cash and cash equivalents of $ 43.0 million as of June 30 , 2026 expected to fund operations into Q4 2027 PHILADELPHIA , Aug. 05 , 2026 ( GLOBE NEWSWIRE ) -- Context Therapeutics Inc. ( " Context " or the " Company " ) ( Nasdaq : CNTX ) , a clinical - stage biopharmaceutical company advancing T cell engaging ( " TCE ” ) bispecific antibodies for solid tumors , today announced its financial results for the second quarter ended June 30 , 2026 , and reported on recent and upcoming business highlights . " During the second quarter , we advanced our pipeline and reported interim Phase 1a data from CTIM - 76 in a limited number of heavily pretreated patients with platinum - resistant ovarian cancer ( " PROC " ) receiving weekly dosing , " said Martin Lehr , Chief Executive Officer of Context . " These data demonstrated encouraging interim efficacy and safety findings . We intend to evaluate CTIM - 76 with every - three - week ( " Q3W " ) dosing in less heavily pretreated PROC patients in the second half of 2026 , aiming to further characterize its clinical profile in a larger and more commercially relevant dataset . " Mr. Lehr added , " We also expect to dose the first patient in our Phase 1 clinical trial evaluating CT - 202 in patients with Nectin - 4 - positive urothelial , colorectal , and triple - negative breast cancers in the third quarter of 2026 , marking an important step in the clinical advancement of our Nectin - 4 x CD3 TCE program . " Recent Pipeline Progress and Upcoming Milestones of Prioritized Clinical Programs : CTIM - 76 : CLDN6 x CD3 TCE Context is evaluating CTIM - 76 as a monotherapy in a Phase 1 trial in patients with PROC . Recent Progress : • April 2026 : The U.S. Food and Drug Administration granted Fast Track Designation for the treatment of PROC in patients that have received all standard of care therapies • June 2026 : Presented interim Phase 1a safety , tolerability and efficacy data with weekly dosing in PROC patients Upcoming Expected Milestones : • Q1 2027 : Initiation of Phase 1b dose expansion trial • Q2 2027 : Phase 1a initial safety , tolerability and efficacy data with Q3W dosing in PROC patients CT - 202 : Nectin - 4 x CD3 TCE Context is evaluating CT - 202 as a monotherapy in a Phase 1 trial in patients with urothelial , colorectal , and triple - negative breast cancers . Recent Progress : • April 2026 : Human Research Ethics Committee approval and Clinical Trial Notification acknowledgement by the Australian Therapeutic Goods Administration to initiate a first - in - human Phase 1 clinical trial • May 2026 : Entered into a License Agreement Amendment with BioAtla , Inc. removing all future milestones and royalty obligations owed Upcoming Expected Milestones : • 3Q 2026 : First patient dosed in Phase 1 trial • 2H 2027 : Phase 1a initial topline safety , tolerability and early efficacy data CT - 95 : MSLN x CD3 TCE As part of a portfolio prioritization and capital allocation strategy , Context is discontinuing the development of CT - 95 and will focus its development efforts on CTIM - 76 and CT - 202 . Second Quarter 2026 Financial Results • Cash and cash equivalents were $ 43.0 million at June 30 , 2026 , compared to $ 66.0 million at December 31 , 2025. The